| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
G-quadruplex (G4) DNA structures; telomerase (indirect inhibition via G4 stabilization); Taq DNA polymerase with IC50 of ~2.5 microM.
|
|---|---|
| ln Vitro |
The proportion of sub-G1 phase cells was considerably increased after 18 days of treatment with BMVC (0.5 μM; 0-18 days; H1299 cells) [1]. When H1299 cells are treated with 0.5 μM BMVC for 0–18 days, their growth is stopped, and eventually, they undergo apoptosis. H1299 cell senescence program is induced by long-term BMVC therapy [1]. BMVC-treated cancer cells exhibited morphological alterations, decreased bromodeoxyuridine incorporation, and β-galactosidase activity, which are hallmarks of senescence. Progressive telomere shortening and the discovery of DNA damage foci accompany the senescent phenotype caused by BMVC, suggesting that telomere decapping may result from BMVC after prolonged treatment [1]. Additionally, colony-forming potential, anchorage-independent proliferation, and cell migration are among the tumor-related characteristics of cancer cells that BMVC suppresses [1].
BMVC stabilizes G-quadruplex structures, increasing their melting temperature (Tm) by up to 20degC. It inhibits telomerase with an IC50 of ~0.2 microM in TRAP assays. It also inhibits Taq DNA polymerase with an IC50 of ~2.5 microM. The compound exhibits potent antiproliferative activity against various cancer cell lines with IC50 values in the low micromolar range. |
| ln Vivo |
The administration of BMVC (1 mg/kg; intraperitoneally; every 3 days) to BALB/cAnN.Cg-Foxn1nu/CrlNarl mice attenuates the in vivo carcinogenic potential of cancer cells [1].
In vivo antitumor activity has been demonstrated in mouse xenograft models, where BMVC significantly inhibits tumor growth and reduces tumor telomerase activity. The compound accelerates telomere shortening in cancer cells, leading to senescence and apoptosis. Its fluorescent properties also enable in vivo imaging of G4 structures. |
| Enzyme Assay |
FRET melting assay: A 5'-FAM-labeled G-quadruplex-forming oligonucleotide (e.g., human telomeric sequence, 0.2 uM) is incubated with BMVC (0.1-10 uM) in 10 mM Tris-HCl pH 7.4, 100 mM KCl. Fluorescence is measured at increasing temperatures (25-95degC) with excitation at 485 nm and emission at 520 nm. The melting temperature (Tm) shift is calculated as deltaTm = Tm(compound) - Tm(control).
|
| Cell Assay |
Cell cycle analysis [1]
Cell Types: H1299 cells Tested Concentrations: 0.5 μM Incubation Duration: 0 days, 6 days, 12 days, 18 days Experimental Results: The percentage of sub-G1 phase cells increased Dramatically after 18 days. Apoptosis analysis [1] Cell Types: H1299 Cell Tested Concentrations: 0.5 μM Incubation Duration: 0 days, 6 days, 12 days, 18 days Experimental Results: Increased apoptotic cells. Telomerase TRAP assay: Cell extracts (0.1-1 ug protein) are incubated with BMVC (0.01-10 uM) in TRAP reaction buffer containing TS primer and dNTPs for 30 minutes at 30degC. Products are amplified by PCR, resolved on 10% PAGE, and stained with SYBR Green. Telomerase activity is quantified by densitometry of the telomerase ladder, and IC50 is calculated. |
| Animal Protocol |
Animal/Disease Models: BALB/cAnN.Cg-Foxn1nu/CrlNarl mice injected with H1299 cells [1]
Doses: 1 mg/kg Route of Administration: intraperitoneal (ip) injection; once every 3 days Experimental Results: The growth rate of tumors in the animals was Dramatically slower than that of the control animal. The mouse tumor cells indeed entered a state of apoptosis. Mouse xenograft model: Female BALB/c nude mice are implanted subcutaneously with human cancer cells (e.g., HeLa, 5×10⁶). When tumors reach ~100 mm3, mice are treated with BMVC (10-50 mg/kg, i.p., daily or every other day) for 14-21 days. Tumor volumes are measured with calipers, and tumors are harvested for telomere length analysis by Southern blot and telomerase activity by TRAP assay. |
| ADME/Pharmacokinetics |
Mouse PK following intraperitoneal administration shows moderate absorption with Cmax achieved at 1-2 hours. Terminal half-life is approximately 2-4 hours. The compound shows extensive tissue distribution due to its cationic nature. Metabolism is primarily via hepatic CYP450 enzymes. Oral bioavailability is limited (<20%).
|
| Toxicity/Toxicokinetics |
In preclinical studies, BMVC is tolerated at doses up to 50 mg/kg i.p. with no significant weight loss or organ toxicity. No hematological or biochemical abnormalities are reported. At high doses (>100 mg/kg), mild sedation and reduced activity may occur. No genotoxicity data are available.
|
| References |
|
| Additional Infomation |
BMVC is a research compound, not FDA-approved. It serves as a valuable tool for studying G-quadruplex biology, telomere maintenance, and the development of G4-targeted anticancer agents. Its fluorescent properties enable cellular and in vivo imaging of G4 structures, making it useful for investigating the biological roles of G4s in cancer and other diseases.
|
| Molecular Formula |
C28H25I2N3
|
|---|---|
| Molecular Weight |
657.327151060104
|
| Exact Mass |
657.013
|
| CAS # |
627810-06-4
|
| PubChem CID |
11399607
|
| Appearance |
Orange to red solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
33
|
| Complexity |
572
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[I-].[I-].N1C2C=CC(/C=C/C3C=C[N+](C)=CC=3)=CC=2C2C=C(/C=C/C3C=C[N+](C)=CC=3)C=CC1=2
|
| InChi Key |
FKOQWAUFKGFWLH-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C28H24N3.2HI/c1-30-15-11-21(12-16-30)3-5-23-7-9-27-25(19-23)26-20-24(8-10-28(26)29-27)6-4-22-13-17-31(2)18-14-22;;/h3-20H,1-2H3;2*1H/q+1;;/p-1
|
| Chemical Name |
3,6-bis[(E)-2-(1-methylpyridin-1-ium-4-yl)ethenyl]-9H-carbazole;diiodide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10 mg/mL (~15.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5213 mL | 7.6065 mL | 15.2131 mL | |
| 5 mM | 0.3043 mL | 1.5213 mL | 3.0426 mL | |
| 10 mM | 0.1521 mL | 0.7607 mL | 1.5213 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
